Day: May 4, 2023

Hyundai Motor Wins Six iF Design Awards for Innovative Digital Communication Content and CES Exhibition

iF Design Award honored Hyundai Motor’s prominent marketing communication efforts for IONIQ 6 video, digital billboard display, website design and online user experience The prestigious international competition also recognized Hyundai IONIQ 5 robotaxi global campaign and booth design for Hyundai Motor’s CES 2022 exhibition SEOUL, South Korea, May 5, 2023 /PRNewswire/ — In a year […]

Legendary Location, Led by the Best: Quark Expeditions Announces Shane Evoy as Snow Hill Expedition Leader for 2023

SEATTLE, May 5, 2023 /PRNewswire/ — Quark Expeditions, the global leader in polar adventures, is excited to announce that renowned polar guide Shane Evoy will serve as Expedition Leader for its voyages to Antarctica’s remote Snow Hill penguin colony in November, 2023. With nearly 30 years of experience in Antarctica, Evoy is one of only […]

Recall Notice – SD Biosensor, Inc. requests discontinuation of use and disposal of specific Pilot™ COVID-19 At-Home Tests in the United States due to microbial contamination in the liquid buffer solution

SEOUL, South Korea, May 5, 2023 /PRNewswire/ — SD Biosensor, Inc. today is requesting that consumers stop using and dispose of specific Pilot COVID-19 At-Home Tests in the United States because potentially harmful bacteria were found in the tube with liquid inside (pouch 2 of the kits). The affected tests can be identified by the […]

ABM Announces First Patient Dosed in Phase I Clinical Trial of MEK Inhibitor for Solid Tumor

SAN DIEGO and SHANGHAI, May 5, 2023 /PRNewswire/ — ABM Therapeutics, an innovative clinical-stage biopharmaceutical company, with an emphasis on developing drugs with high blood–brain barrier (BBB) penetration for CNS diseases including brain metastases, today announced that the first patient was successfully dosed with ABM-168 in the United States. MEK (mitogen-activated protein kinase kinase), a […]

SNIPR Biome’s data on first clinical drug candidate to prevent infections in hematological cancer patients published in Nature Biotechnology

SNIPR001 is a novel CRISPR-Cas therapeutic designed to selectively target antibiotic resistant E. coli, which can cause fatal infections in vulnerable hematological cancer patients             SNIPR001 represents the first CRISPR- therapeutic developed to specifically remove E. coli in the human gut             In vitro studies showed SNIPR001 […]

Back To Top